Axol Bioscience Secures £3.2 Million Funding for iPSC-Derived Cell Technologies

Axol Bioscience, a UK-based provider of iPSC-derived cells, media, and characterization services for life science discovery, has raised £3.2 million in funding

The round, an extension of its previous funding round, bringing the total raised to £7 million, was led by existing investors Calculus Capital, Par Equity and Scottish Enterprise, with support from Meltwind

The funds will be used to bring new human induced pluripotent stem cell (iPSC) products and service solutions to the drug discovery and screening markets

Funding will also enable the company to further optimize cell culture quality and iPSC manufacturing capabilities, as well as support recruitment efforts to expand its commercial team.